This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Improving Adherence in Patients With Hypertension - A Novel Use of Communication Technology

This study has been completed.
Information provided by (Responsible Party):
Joseph C. Kvedar, Massachusetts General Hospital Identifier:
First received: January 13, 2006
Last updated: February 27, 2013
Last verified: February 2013
Treating hypertension is known to decrease morbidity and mortality. Despite this 70% of patients do not have adequately controlled blood pressure. The main reason for this is non-adherence to recommended drug therapy. Although strategies have been developed to improve adherence many are time consuming and expensive. We propose to use communications technology to develop a novel means of improving adherence to antihypertensive therapy. We will conduct a randomised, single-blinded, controlled study to assess the impact of a real-time, automated reminder system on adherence rates. This will involve adapting two pieces of currently available technology - the electronic pill bottle and the Ambient Globe. The Globe will change colour in response to information received, via a wireless link, from the patient's electronic pill bottle. We hypothesise that this will provide patients with an up to date, but unobtrusive, reminder of their adherence status and thus effect positive behavioural change. We will measure the impact of this intervention on adherence rates as well as assessing patient views and the impact on provider workload. This trial will elucidate the role of communications technology in improving adherence behaviour and allow us to develop further strategies to tackle this major health issue.

Condition Intervention
Hypertension Behavioral: Automated feedback regarding drug adherence

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind
Official Title: Improving Adherence in Patients With Hypertension - A Novel Use of Communication Technology

Further study details as provided by Joseph C. Kvedar, Massachusetts General Hospital:

Primary Outcome Measures:
  • Adherence rates as measured using data held in the SIMpill database
  • Patient satisfaction with intervention as assessed by questionnaire at the end of the study.
  • Technical difficulties as assessed by interview at the end of the study and by review of the technical log.

Secondary Outcome Measures:
  • Discontinuation rates of medication as assessed at the end of trial debrief.
  • Changes to medication regime as assessed at the end of trial debrief.
  • Adverse events (e.g. hospitalisation) as assessed from the log of withdrawals from the trial.
  • Blood pressure as measured on enrollment and at end of trial debrief.

Enrollment: 84
Study Start Date: July 2006
Study Completion Date: January 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   45 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Prescription of a once-a-day dose of atenolol.
  • Morisky Score of less than or equal to 2 (explanation in 'Equitable Selection of Subjects').
  • Fluency in English.
  • Age 45-65 inclusive.
  • Primary Care Physician consent to the patient taking part.

Exclusion Criteria:

  • Patients prescribed more than two anti-hypertensive agents.
  • Patients prescribed more than four medications in total.
  • Patients on secondary prevention following cardiac event or stroke.
  • Morisky Score of more than 2.
  • Patients with visual impairment or color-blindness.
  • Patients with congenital or acquired cognitive impairment.
  • Patients with a cardiac pacemaker
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00277381

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Joseph C. Kvedar, MD Partners Healthcare System
  More Information

Responsible Party: Joseph C. Kvedar, Director, Center for Connected Health, Massachusetts General Hospital Identifier: NCT00277381     History of Changes
Other Study ID Numbers: 2005-P-002248
Study First Received: January 13, 2006
Last Updated: February 27, 2013

Keywords provided by Joseph C. Kvedar, Massachusetts General Hospital:

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases processed this record on August 16, 2017